Samjin Pharmaceuticals Co., Ltd. - Laporan Laba Rugi (TTM)

Samjin Pharmaceuticals Co., Ltd.
KR ˙ KOSE ˙ KR7005500004
₩ 19,000.00 ↓ -10.00 (-0.05%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Samjin Pharmaceuticals Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2021
12-31
2022
12-31
Revenue 250,070 274,032
Change (%) 9.58
% of Revenue 100.00 100.00
Cost Of Sales 132,238 156,297
Change (%) 18.19
% of Revenue 52.88 57.04
Gross Operating Profit 117,832 117,734
Change (%) -0.08
% of Revenue 47.12 42.96
SG&A 79,936 89,197
Change (%) 11.58
% of Revenue 31.97 32.55
R&D 2,582 3,658
Change (%) 41.67
% of Revenue 1.03 1.33
OpEx 216,159 250,848
Change (%) 16.05
% of Revenue 86.44 91.54
Operating Income 33,911 23,184
Change (%) -31.63
% of Revenue 13.56 8.46
Interest Expense -142 -1,763
Change (%) 1,142.39
% of Revenue -0.06 -0.64
Net Income 28,404 21,894
Change (%) -22.92
% of Revenue 11.36 7.99

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista